相似文献
1
Called to account.
Nature. 2004 Jul 8;430(6996):133. doi: 10.1038/430133a.
2
HIV/AIDS. The great funding surge.
Science. 2008 Jul 25;321(5888):512-9. doi: 10.1126/science.321.5888.512.
3
Out of Thailand, into Africa.
Nature. 2004 Jul 8;430(6996):136-7. doi: 10.1038/430136a.
4
Dispatches from the front line.
Nature. 2002 Aug 1;418(6897):465. doi: 10.1038/418465a.
5
Uganda cuts AIDS drug deal.
IAPAC Mon. 2001 Feb;7(2):40.
6
Cutbacks threaten HIV gains.
Nature. 2011 Dec 8;480(7376):159-60. doi: 10.1038/480159a.
7
How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?
Clin Infect Dis. 2006 Feb 1;42(3):431-2; author reply 432-3. doi: 10.1086/499527.
8
[HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
Med Klin (Munich). 2003 Jul 15;98(7):XV-XVI.
9
Cost-effectiveness of HIV therapies in different economic worlds.
AIDS Read. 2001 May;11(5):236-7.
10
Cuts hamper bid to tackle AIDS.
Nature. 2012 Mar 6;483(7388):131-2. doi: 10.1038/483131a.
Zotero 插件